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Technological advances in mass spectrometry instrumentation and proteomics methodologies are
moving the field of clinical proteomics towards the analysis of large numbers of patient samples in
a reasonable time. The Special Issue ‘Clinical proteomics’ reviews the current proteomic work flow
from biological sample preparation to clinical exploitation with samples collected from human body
fluids, tissues or isolated cells, and highlights the trend towards integrated omics approaches for
clinical usage.
Hernandez-Valladaras and colleagues [1] provide an overview of sample processing methods for
acute myeloid leukemia cells (AML) harvested in bone marrow and peripheral blood from patients
suffering from hematopoietic disease. AML biomarkers are promising targets for diagnostic and
prognostic purposes enabling individual treatment regimens and identifying patients requiring bone
marrow transplant. The review article compares the performance of urea-based lysis methods versus
the filter-aided sample preparation (FASP) procedures and concludes that FASP-based procedures
outperform standard in-solution digestion procedures and recommends to explore sample preparation
methods for other cancer cells before analysing large patient cohorts. Peptide fractionation of AML
protein digests is encouraged for obtaining in depth proteomes and phosphoproteomes by combining
FASP with C18 STAGE tip fractionation steps and with IMAC as phosphopeptide enrichment step.
Sample processing and bioanalytical workflows dedicated to phosphoproteome analysis of
traditional human biological fluids such as serum/plasma, urine, cerebrospinal fluid (CSF), saliva and
broncoalveolar lavage fluid are discussed by Giorginanni and Beranova-Giorgianni [2], together with
an overview in protein depletion methods for the detection of low abundant biomarkers. Multiple
Affinity Removal System (MARS) is a popular immuno-affinity column for specific removal of
abundant proteins, despite the possibility of depleting some off-target proteins. ProteoMiner protein
enrichment technology is another depletion approach that allows for detection of equal protein
amounts within a complex protein sample by employing a bead-based library of combinatorial peptide
ligands to concentrate low abundance proteins to specific peptide ligands and dilute high abundance
proteins by washing off excess protein after saturating specific peptide ligands. The authors review
phosphoproteome applications for a variety of diseases (various cancers and neurological disorders)
and conclude that clinical applications are largely unexplored and partly complicated by the plethora
of bioanalytical workflows currently in use, and they foresee a move to simpler workflows relying on
‘single shot’ analyses with extended liquid chromatography LC gradients.
Sample handling procedures of non-traditional human samples such as ear wax, saliva, vitreous
humor, aqueous humor, tears, nipple aspirate fluid, breast milk / colostrum, cervical-vaginal fluid,
nasal secretions, bronco-alveolar lavage fluid, and stools for the utilization in quantitative proteomic
studies for diagnostic and disease treatment purposes are reviewed by Licier et al. [3]. The article
provides an excellent overview of various protein labelling methods for quantitative proteomics and
recent clinical research work conducted with the non-traditional samples.
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Trenchevska et al. [4] discuss a targeted sample processing approach for intact proteins isolated
from human samples by Mass Spectrometric Immunoassay (MISA), the mass spectrometric equivalent
of the Enzyme-Linked Immunosorbent Assay (ELISA). In this assay microcolumns are immobilised
with antibodies to capture target proteins from complex biological samples that are detected by
MALDI-TOF MS or ESI MS after rinsing the affinity pipette to remove non-specifically bounded
proteins. Quantitative MISA experiments require co-immobilisation of an internal reference standard
with an antibody towards the target protein that is exogenous to human body fluids, for example
directed against protein derivatives (His-tagged proteins), or directed against homologues proteins
from other animal species. Exogenous protein is spiked into samples as protein standard for absolute
quantification. The authors focus on MISA applications of clinically significant proteoisoforms arising
from alternative splicing, single nucleotide polymorphisms (SNPs) and post translational modifications.
Some of the well-established disease biomarkers such as cystatin C, prostate-specific antigen and
cardiac troponin exist in several forms in vivo. The potential of this method is demonstrated by
published MISA experiments for more than 20 protein targets, where the authors highlight their
own contributions showing detection of Serum amyloid A (SAA) protein isoforms from individuals
expressing various polymorphic variants as distinct peaks in MALDI-TOF mass spectra.
Apolipoproteins have also been shown to exist in vivo in several proteoisoforms, which are
involved in lipid metabolism, and are associated with cardiovascular diseases, type 2 diabetes and
Alzheimer Disease (AD). Martins [5] argues that the observed variation in the detection of Apo E
isoforms by clinical proteomics of various proteins in body fluids, originates from biological variation
rather than from technical variation. Complementary technologies utilising genomics and lipidomics
are therefore crucial for early stage diagnosis by revealing abnormalities in cholesterol levels and
lipoprotein metabolism that are associated with cognitive and behavioral symptoms in later AD stages.
Clinical genomics testing for Apo E is important for diagnosis avoiding errors by proteomics testing
from the biological variation in amyloid beta and Apo E protein expression. Clinical lipidomics testing
of plasma, tissue and CSF samples have provided reproducible results for the diagnosis of various
neurological diseases including AD, which are also linked to chronic diseases. These complementary
diagnostic tests suggest that nuclear receptors crucially determine the links between insulin resistance,
chronic disease and AD, such as the downregulation of the calorie-sensitive anti-aging nuclear receptor
Sirt1 in early stage of AD. The link between cholesterol and developing AD opens the door for treatment
with nutritional diets maintaining cholesterol homeostasis. Nutritional proteomics research showed
that AD plasma biomarkers are regulated by low fat diets through activation of Sirt1 preventingamyloid
beta aggregation and induced inflammation.
The notion that detailed insights in cellular homeostasis and disease progression are generated
from studies applying clinical proteomics with complementary omics technologies inspired Bosman
for outlining the current perspective of red blood cell (RBC) homeostasis by integrating proteome with
metabolome data [6]. Comparative proteomics studies have generated erythrocyte protein inventories
and provided new insights in mechanisms controlling red blood cell morphology under pathological
conditions. Protein kinase activities and signalling networks regulate pathology-associated changes
in phosphorylation status of erythrocyte cytoskeleton proteins, such as band 3, and RBC membrane
structure. Proteomics of the erythrocyte cytosolic fraction identified not only metabolic enzymes
involved in glycolysis and pentose phosphate pathway but also protein-repair enzymes. These
enzymes are thought to be assembled in multiprotein complexes regulating oxygen transport,
metabolism, anti-oxidant activity and protein breakdown. Metabolomics data suggests that CO2
concentrations are also associated with the multiprotein complexes besides oxygen. The combination
of proteome and metabolome data alludes to a mechanism with central roles for molecular interactions
at the red cell surface regulating cell shape, deformability, cell survival, and metabolism with oxygen
and CO2 transport. Support for this proposed mechanism comes from observations that glycolysis and
the pentose phosphate pathway are regulated by oxygen-driven interactions of key enzymes with the
membrane, and that binding between cytoskeleton and membrane is controlled by oxygen-mediated
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interaction between band 3 and ankyrin. Recent studies further establish relations between metabolic
changes and erythrocyte pathologies, which are likely caused by changes in membrane-associated
protein complexes.
The holistic view of the utilization of complementary mass spectrometry-based technologies
in personalized proteomics for clinical diagnosis and treatment is seen by Duarte and Spencer [7]
as the future for personalized medicine. Genomics information alone is insufficient for diagnosing
multifactorial diseases such as AD by the inherent inability in gathering all information that predict
physiological states of patients, such as protein expression patterns, protein-protein interactions, PTMs
and metabolites. Current limitations for personalized proteomics in clinical practice are technological
complexity of the analyses involved and lack of standardisation for sample processing procedures [1–4]
and mass spectrometry methodology [1–3,7]. Furthermore, translation of proteomics-based biomarker
discovery research into the clinic has been limited by failures in the validation phase in testing large
patient cohorts. More integration of biomarker discovery phase research with clinical studies will lead
to the implementation of validated biomarker assays in clinical practice and move clinical proteomics
out of its infancy.
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